Trial reportClinical and experimental immunology2002
Plasma levels of soluble endothelial cell protein C receptor in patients with Wegener's granulomatosis.
Trial report in Clinical and experimental immunology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 24 citations in OpenAlex.
- Associations between hemostatic markers and mortality in COVID-19 - Compounding effects of D-dimer, antithrombin and PAP complex.Thrombosis research · 2022Article
- The endothelial protein C receptor rs867186-GG genotype is associated with increased soluble EPCR and could mediate protection against severe malaria.Scientific reports · 2016Article
- Thrombosis in vasculitis: from pathogenesis to treatment.Thrombosis journal · 2015Article
- Organ-specific protection against lipopolysaccharide-induced vascular leak is dependent on the endothelial protein C receptor.Arteriosclerosis, thrombosis, and vascular biology · 2013Article
- Soluble endothelial cell protein C receptor and thrombomodulin levels after renal transplantation.International urology and nephrology · 2010Article
- Anti-neutrophil cytoplasmic antibodies target sequential functional proteinase 3 epitopes in the sera of patients with Wegener’s granulomatosis.Clinical and experimental immunology · 2010Article
- Clinical implications of serum thrombomodulin in PR3-ANCA-associated vasculitis.European journal of medical research · 2009Article
- Soluble endothelial protein C receptor levels in Behçet patients with and without ocular involvement.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2008Article
- Proteolysis of the endothelial cell protein C receptor by neutrophil proteinase 3.Journal of thrombosis and haemostasis : JTH · 2007Article
- Antiendothelial cell antibodies in vasculitis and connective tissue disease.Annals of the rheumatic diseases · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
Abstract
Elevated soluble thrombomodulin (sTM) levels are an accepted marker of endothelial damage. The physiological significance of plasma endothelial protein C receptor (sEPCR) levels is not known. To assess the relevance of this plasma protein in Wegener's granulomatosis (WG), sEPCR levels were measured in sera obtained from WG patients and related to disease activity, sTM levels, and other known markers of disease activity. In total, 129 sera (37 at active disease, 92 during follow-up) from 31 WG patients were tested. During active disease, eight (22%) and 17 (46%) out of 37 active sera had elevated levels of sEPCR and sTM, respectively (NS); sEPCR (r = 0.39; P = 0.02) and sTM (r = 0.53; P <0.01) levels correlated with disease activity (Birmingham Vasculitis Activity Score). Analysis of longitudinal sera revealed a significant increase in sEPCR (P = 0.01) and sTM (P = 0.04) levels prior to the moment of a relapse. Corrected for renal function, the increase in sEPCR remained significant (P =0.04) whereas sTM did not (NS). Levels of sEPCR correlated with sTM levels (r = 0.32; P < 0.001). Plasma levels of sEPCR respond to changes in the disease in patients with WG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.